The difference between methotrexate and TNF inhibitors responses: where is the margin of benefit at 52 weeks*?
| Clinical trial | Clinical endpoint ACR 20 response (%) | Radiographic endpoint No radiographic progression (%) | ||||
|---|---|---|---|---|---|---|
| MTX | TNFi | Margin† | MTX | TNFi | Margin† | |
| *Results from references 11–13 | ||||||
| ‡No progression in erosion score. | ||||||
| †Margin of benefit = TNFi result − MTX result. | ||||||
| ACR, American College of Rheumatology; MTX, methotrexate; TNFi, tumour necrosis factor inhibitor. | ||||||
| TEMPO | 75 | 76 | +1 | 57 | 68 | +11 |
| ERA | 65 | 72 | +7 | 60 | 72‡ | +12 |
| ASPIRE | 54 | 62 | +8 | 45 | 58 | +13 |
| PREMIER | 63 | 54 | −9 | 37 | 51 | +14 |